MindBio Therapeutics (CSE:MBIO; Frankfurt:WF6) received its first batch of MB22001 ready for take-home use in Phase 2 psychedelic microdosing clinical trials. MB22001 is a proprietary titratable form of lysergic acid...
Search results for - mindbio
MindBio pre-screening patients in take-home LSD-microdosing Phase 2 study
MindBio Therapeutics Corp (CSE:MBIO; Frankfurt:WF6) started pre-screening for participant entry into Phase 2 LSD-microdosing clinical trials. The clinical trials are a world first with approvals for take home use of...
MindBio gets ethics okay for take-home LSD-microdosing trial in MDD
MindBio Therapeutics (CSE:MBIO; Frankfurt:WF6) received ethics approval for a world’s first Phase 2a take-home LSD-microdosing clinical trial in patients with major depressive disorder (MDD) in New Zealand. The...
MindBio Therapeutics lists on CSE
MindBio Therapeutics (CSE:MBIO; Frankfurt:WF6) has listed its common shares on the Canadian Securities Exchange under the ticker symbol, MBIO. MindBio is the only company in the world to have clinical trials approved...
